Regression of Neuropsychological Deficits in Early-treated Phenylketonurics During Adolescence

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 1999 Sep 3

PMID 10472530

Citations 6

Authors

J Weglage

M Pietsch

J Denecke

A Sprinz

R Feldmann

M Grenzebach

K Ullrich

Affiliations

Soon will be listed here.

Abstract

Even early-treated phenylketonuric patients suffer from phenylalanine-associated (mild) neuropsychological impairment. To date it is still unclear whether patients' deficits show a progression on ageing. This unsolved question seems to be an important aspect in the still ongoing debate about how long and how strictly the patients should be maintained on diet. Twenty early-treated (20 +/- 10, 9-30 days) adolescent phenylketonurics (10 boys, 10 girls) and 20 healthy controls, matched for age, sex and IQ, were investigated twice at a mean ages of 11 and 14 years for their IQ (Culture Fair Intelligence Test-Scale 2; CFT-20), fine motor abilities (Motor Performance Task), sustained (Test d2) and selective attention (Stroop-Task). At the first test, examinations revealed significant blood phenylalanine-correlated neuropsychological deficits in PKU patients. In spite of raised blood phenylalanine concentrations during the following 3 years and significantly elevated concurrent blood phenylalanine concentrations, the repeated measurements revealed a significant decrease of patients' deficits compared to controls. Clinical-neurological status of patients and controls was normal at both test times. The results indicate a decreased vulnerability of PKU-patients with respect to their neuropsychological functioning against elevated blood phenylalanine levels on ageing.

Citing Articles

Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Medford E, Hare D, Wittkowski A JIMD Rep. 2017; 39:107-116.

PMID: 28840576 PMC: 5953888. DOI: 10.1007/8904_2017_52.

Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Manti F, Nardecchia F, Paci S, Chiarotti F, Carducci C, Carducci C J Inherit Metab Dis. 2017; 40(6):793-799.

PMID: 28836033 DOI: 10.1007/s10545-017-0082-y.

Host conditioning and rejection monitoring in hepatocyte transplantation in humans.

Soltys K, Setoyama K, Tafaleng E, Soto Gutierrez A, Fong J, Fukumitsu K J Hepatol. 2016; 66(5):987-1000.

PMID: 28027971 PMC: 5395353. DOI: 10.1016/j.jhep.2016.12.017.

Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Fonnesbeck C, McPheeters M, Krishnaswami S, Lindegren M, Reimschisel T J Inherit Metab Dis. 2012; 36(5):757-66.

PMID: 23197105 DOI: 10.1007/s10545-012-9564-0.

Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Sundermann B, Pfleiderer B, Moller H, Schwindt W, Weglage J, Lepsien J J Inherit Metab Dis. 2011; 34(3):711-21.

PMID: 21491106 DOI: 10.1007/s10545-011-9318-4.

References

Weglage J, Funders B, Wilken B, Schubert D, Schmidt E, Burgard P . Psychological and social findings in adolescents with phenylketonuria. Eur J Pediatr. 1992; 151(7):522-5. DOI: 10.1007/BF01957759. View

Holtzman N, Kronmal R, van Doorninck W, Azen C, Koch R . Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. N Engl J Med. 1986; 314(10):593-8. DOI: 10.1056/NEJM198603063141001. View

Smith I . Treatment of phenylalanine hydroxylase deficiency. Acta Paediatr Suppl. 1994; 407:60-5. DOI: 10.1111/j.1651-2227.1994.tb13453.x. View

Griffiths P, Campbell R, Robinson P . Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test. J Inherit Metab Dis. 1998; 21(2):125-35. DOI: 10.1023/a:1005339524847. View

Welsh M, Pennington B, Ozonoff S, Rouse B, McCabe E . Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev. 1990; 61(6):1697-713. View

Bench C, Frith C, Grasby P, Friston K, Paulesu E, Frackowiak R . Investigations of the functional anatomy of attention using the Stroop test. Neuropsychologia. 1993; 31(9):907-22. DOI: 10.1016/0028-3932(93)90147-r. View

Ris M, Weber A, HUNT M, BERRY H, Williams S, Leslie N . Adult psychosocial outcome in early-treated phenylketonuria. J Inherit Metab Dis. 1997; 20(4):499-508. DOI: 10.1023/a:1005389110739. View

Hommes F . Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. Acta Paediatr Suppl. 1994; 407:120-1. DOI: 10.1111/j.1651-2227.1994.tb13469.x. View

HUTTENLOCHER P . Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res. 1979; 163(2):195-205. DOI: 10.1016/0006-8993(79)90349-4. View

10.

Cleary M, Walter J, Wraith J, Jenkins J, Alani S, Tyler K . Magnetic resonance imaging of the brain in phenylketonuria. Lancet. 1994; 344(8915):87-90. DOI: 10.1016/s0140-6736(94)91281-5. View

11.

Smith I, Beasley M, Ades A . Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child. 1991; 66(3):311-6. PMC: 1792859. DOI: 10.1136/adc.66.3.311. View

12.

Weglage J, Pietsch M, Funders B, Koch H, Ullrich K . Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions?. Eur J Pediatr. 1996; 155(3):200-4. DOI: 10.1007/BF01953938. View

13.

Pietz J, Fatkenheuer B, Burgard P, Armbruster M, Esser G, Schmidt H . Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics. 1997; 99(3):345-50. DOI: 10.1542/peds.99.3.345. View

14.

. Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch Dis Child. 1993; 68(3):426-7. PMC: 1793880. DOI: 10.1136/adc.68.3.426. View

15.

Schmidt E, Burgard P, Rupp A . Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. Eur J Pediatr. 1996; 155 Suppl 1:S82-6. DOI: 10.1007/pl00014258. View

16.

Burgard P, Schmidt E, Rupp A, Schneider W, Bremer H . Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr. 1996; 155 Suppl 1:S33-8. DOI: 10.1007/pl00014245. View

17.

Milner J, Irie K, Wurtman R . Effects of phenylalanine on the release of endogenous dopamine from rat striatal slices. J Neurochem. 1986; 47(5):1444-8. DOI: 10.1111/j.1471-4159.1986.tb00777.x. View

18.

Waisbren S, Brown M, de Sonneville L, Levy H . Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. Acta Paediatr Suppl. 1994; 407:98-103. DOI: 10.1111/j.1651-2227.1994.tb13464.x. View

19.

QUATEMBER R, Maly J . [Neuropsychological methods of examination of age-specific performance parameters (author's transl)]. Wien Med Wochenschr. 1980; 130(21):688-92. View

20.

Lou H, Lykkelund C, Gerdes A, Udesen H, Bruhn P . Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand. 1987; 76(4):560-5. DOI: 10.1111/j.1651-2227.1987.tb10521.x. View